Drug Trial Radar · NCT07521657
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Jan 1, 2031
Study completion Jan 1, 2032
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Children's Hospital of Philadelphia; Congressionally Directed Medical Research Programs
- First posted
- Apr 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a newly diagnosed GBM (Cohort 2); mirdametinib alone in other NF1-associated High-Grade Gliomas (Cohort 3).
Conditions
- Neurofibromatosis 1 (NF1)
Interventions
mirdametinib with radiationCombination product
Participants in Cohorts 1 and 2 will receive mirdametinib in combination with radiation therapy followed by mirdametinib alone.
mirdametinibDrug
Participants in Cohort 3 will receive mirdametinib alone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1Time frame: From treatment to 12 months
- Cohort 2Time frame: From treatment to 18 months
- Cohort 3Time frame: From treatment to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Childrens of Alabama
Birmingham, Alabama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.